BDBM246220 US10183932, Example 144::US9434690, 125::US9434690, 141::US9434690, 142::US9434690, 143::US9434690, 144::US9822102, Example 144

SMILES CCC(CC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C#N)OC

InChI Key InChIKey=NWTLKQWFPQKMLC-UHFFFAOYSA-N

Data  30 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 30 hits for monomerid = 246220   

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 23nMAssay Description:To determine the factor XIa inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reaction of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 1.00E+3nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 4.60nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 18nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 1.60E+3nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 23nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 98nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 0.600nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 3.90nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 190nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 3.60nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 1.00E+3nMAssay Description:To determine the factor XIa inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reaction of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 4.60nMAssay Description:To determine the factor XIa inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reaction of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 18nMAssay Description:To determine the factor XIa inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reaction of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 1.60E+3nMAssay Description:To determine the factor XIa inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reaction of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 3.60nMpH: 7.4 T: 2°CAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2017
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 98nMAssay Description:To determine the factor XIa inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reaction of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 0.600nMAssay Description:To determine the factor XIa inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reaction of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 3.90nMAssay Description:To determine the factor XIa inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reaction of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 190nMAssay Description:To determine the factor XIa inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reaction of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 3.60nMAssay Description:To determine the factor XIa inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reaction of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 4.60nMpH: 7.4 T: 2°CAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 1.60E+3nMpH: 7.4 T: 2°CAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 1.00E+3nMpH: 7.4 T: 2°CAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 18nMpH: 7.4 T: 2°CAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 23nMpH: 7.4 T: 2°CAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2017
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 98nMpH: 7.4 T: 2°CAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2017
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 3.90nMpH: 7.4 T: 2°CAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2017
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 0.600nMpH: 7.4 T: 2°CAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2017
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246220(US9434690, 125 | US9434690, 144 | US9434690, 143 |...)
Affinity DataIC50: 190nMpH: 7.4 T: 2°CAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2017
Entry Details
Go to US Patent